Burning Rock Biotech Ltd (BNR) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $14.23 (+5.29%), Market cap $0.18B, 52-week low–high $2.72 ~ $41.06.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-ge
Financial statements, price targets, institutional (13F) holdings and related news for Burning Rock Biotech Ltd are updated in real time on BlackAll Trade.
Burning Rock Biotech Ltd trades at $14.23 (+5.29%). Real-time quotes and charts are available on BlackAll Trade.
Burning Rock Biotech Ltd has a market cap of about $0.18B.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-H